In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 26 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Speech analysis to evaluate acute heart failure patient clinical status

Session HFA Discoveries - ePosters

Speaker Ronit Haviv

Event : HFA Discoveries 2020

  • Topic : e-cardiology / digital health, public health, health economics, research methodology
  • Sub-topic : Remote Patient Monitoring and Telemedicine
  • Session type : ePoster

Authors : O Amir (Jerusalem,IL), WT Abraham (Ohio,US), ZS Azzam (Haifa,IL), SD Anker (Berlin,DE), SP Pinney (New York,US), D Burkhoff (New York,US), ID Shallom (Or Yehuda,IL), C Lotan (Jerusalem,IL), ER Edelman (Boston,US)

Authors:
O Amir1 , WT Abraham2 , ZS Azzam3 , SD Anker4 , SP Pinney5 , D Burkhoff6 , ID Shallom7 , C Lotan1 , ER Edelman8 , 1Hadassah University Medical Center - Jerusalem - Israel , 2Ohio State University Hospital - Ohio - United States of America , 3Rambam Health Care Campus - Haifa - Israel , 4Charite - Campus Virchow-Klinikum (CVK) - Berlin - Germany , 5Mount Sinai Hospital - New York - United States of America , 6Cardiovascular Research Foundation - New York - United States of America , 7Cordio Medical - Or Yehuda - Israel , 8Institute for Medical Engineering and Science, Massachusetts Institute of Technology - Boston - United States of America ,

Citation:

Background/Introduction

Pulmonary congestion that accompanies heart failure (HF) can produce subtle changes in speech patterns, the measurement of which may be a valuable tool for assessing a HF patient clinical status.

Purpose

We investigated how speech signal processing algorithms detect these changes in patients with acute HF (AHF) throughout their admission and evaluate the potential clinical utility of this approach.

Methods

We recruited 40 patients admitted with AHF mean age 75 ±12 (50% female) and mean LVEF 53 ±15. We studied the use of speech processing algorithms in digitally measured speech samples in these AHF patients at hospital admission ("wet") and discharge ("dry"). Patients were discharged after diuretic treatment and clinical improvement.

We analyzed speech patterns, expressed as numerical values denoted "speech measures" (SM), in a single arm, open label, non-interventional study.  Each patient read out loud and recorded 3-5 prescribed sentences while wet and dry. These recordings underwent processing using a range of algorithms to report five different SMs, denoted SM1, SM2, SM3, SM4 and SM5. Data were presented as SM at admission (SMa), SM at discharge (SMd), and Delta SMs (DSMs) defined as the relative change from admission to discharge, i.e. (SMd-SMa)/SMa.

Results

Speech processing detected a substantial mean change in the 5 SMs between wet and dry states, (Figure 1, p<0.001).

Conclusion

Speech processing provided a clear signal difference between the congested wet state at admission and the compensated dry state at discharge, in these AHF patients. Such digital speech processing offers a readily available, non-invasive means of monitoring congestion and HF clinical status in HF patients that may be implemented in the hospital, in the clinic or in the outpatient setting.

This content is currently on FREE ACCESS, enjoy another 26 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are